Summary
The aim of this project is to expand upon a newly discovered platform reaction by developing new routes to Active Pharmaceutical Ingredients (APIs) Tolterodine and Ezetimibe and other advanced intermediates for the manufacture of drugs (i.e. benzylic fluorides and alcohols). It is planned that this platform will serve to enhance the competitveness of the European pharmaceutical manufacturing industry as it continues to face increased competition from other economies
In order to achieve this aim we need to bring together expertise in
(i) Organic Synthesis [Royal College of Surgeons in Ireland, “RCSI”]
(ii) Enantioselective fluorination [Nagoya University Japan, “Nagoya”]
(iii) Drug development and production [Integrated Research in Biotechnology & Medicine, “IRBM”]
To meet the aim we have divided the project into the following work packages:
WP1: Development of a new synthesis of Tolterodine.
WP2: Scale up of synthesis of Tolterodine.
WP3: Development of a new synthesis of Ezetimibe.
WP4: Scale up of synthesis of Ezetimibe.
WP5: Exemplification of alkoxylation to prepare enantiopure benzylic alcohols API intermediates
WP6: Preparation of benzylic fluorides
WP7: Management, Training, Dissemination & Communication
In order to achieve this aim we need to bring together expertise in
(i) Organic Synthesis [Royal College of Surgeons in Ireland, “RCSI”]
(ii) Enantioselective fluorination [Nagoya University Japan, “Nagoya”]
(iii) Drug development and production [Integrated Research in Biotechnology & Medicine, “IRBM”]
To meet the aim we have divided the project into the following work packages:
WP1: Development of a new synthesis of Tolterodine.
WP2: Scale up of synthesis of Tolterodine.
WP3: Development of a new synthesis of Ezetimibe.
WP4: Scale up of synthesis of Ezetimibe.
WP5: Exemplification of alkoxylation to prepare enantiopure benzylic alcohols API intermediates
WP6: Preparation of benzylic fluorides
WP7: Management, Training, Dissemination & Communication
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/734361 |
| Start date: | 01-01-2017 |
| End date: | 31-12-2020 |
| Total budget - Public funding: | 292 500,00 Euro - 292 500,00 Euro |
Cordis data
Original description
The aim of this project is to expand upon a newly discovered platform reaction by developing new routes to Active Pharmaceutical Ingredients (APIs) Tolterodine and Ezetimibe and other advanced intermediates for the manufacture of drugs (i.e. benzylic fluorides and alcohols). It is planned that this platform will serve to enhance the competitveness of the European pharmaceutical manufacturing industry as it continues to face increased competition from other economiesIn order to achieve this aim we need to bring together expertise in
(i) Organic Synthesis [Royal College of Surgeons in Ireland, “RCSI”]
(ii) Enantioselective fluorination [Nagoya University Japan, “Nagoya”]
(iii) Drug development and production [Integrated Research in Biotechnology & Medicine, “IRBM”]
To meet the aim we have divided the project into the following work packages:
WP1: Development of a new synthesis of Tolterodine.
WP2: Scale up of synthesis of Tolterodine.
WP3: Development of a new synthesis of Ezetimibe.
WP4: Scale up of synthesis of Ezetimibe.
WP5: Exemplification of alkoxylation to prepare enantiopure benzylic alcohols API intermediates
WP6: Preparation of benzylic fluorides
WP7: Management, Training, Dissemination & Communication
Status
CLOSEDCall topic
MSCA-RISE-2016Update Date
28-04-2024
Images
No images available.
Geographical location(s)
